Screen Shot 2017-05-23 at 6.00.58 PM

Anaconda Biomed, a pre-clinical stage medical device company, closed a €15 million Series A financing. It was backed by new investors including Ysios Capital, Banco Sabadell, and Omega Funds, in addition to current investor Innogest Capital.

Anaconda Biomed is based in Barcelona, Spain and was founded in 2015. It works to develop neuro-thrombectomy systems for the treatment of Acute Ischemic Stroke (AIS).

The company says it will use the €15 million to continue advancing the ANCD BRAIN™, a 3rd Generation Stented Aspiration Thrombectomy System for the treatment of AIS. Josep L. Sanfeliu, General Partner at Ysios Capital, and Claudio Nessi, Managing Director at Omega Funds, will also join Anaconda Biomed’s Board of Directors.

“This financing provides Anaconda Biomed the capital necessary to substantially progress the development of our ANCD BRAIN™ device, including the validation and verification process, clinical studies to support the initial commercialization of ANCD BRAIN™ in Europe, and an initial submission to FDA,” said Ofir Arad, Co-Founder and CEO of Anaconda Biomed, in a statement.

Anaconda BioMed

Comments are closed.